Molecular Partners Valuation
| MOLN Stock | CHF 5.10 0.28 5.81% |
At this time, the firm appears to be overvalued. Molecular Partners secures a last-minute Real Value of ₣4.2 per share. The latest price of the firm is ₣5.1. Our model forecasts the value of Molecular Partners from analyzing the firm fundamentals such as Return On Equity of 0.62, profit margin of 0.62 %, and Current Valuation of (39.23 M) as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Molecular Partners' price fluctuation is risky at this time. Calculation of the real value of Molecular Partners is based on 3 months time horizon. Increasing Molecular Partners' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Molecular stock is determined by what a typical buyer is willing to pay for full or partial control of Molecular Partners AG. Since Molecular Partners is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Molecular Stock. However, Molecular Partners' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 5.1 | Real 4.2 | Hype 5.1 | Naive 5.55 |
The intrinsic value of Molecular Partners' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Molecular Partners' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Molecular Partners AG helps investors to forecast how Molecular stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Molecular Partners more accurately as focusing exclusively on Molecular Partners' fundamentals will not take into account other important factors: Molecular Partners Total Value Analysis
Molecular Partners AG is now anticipated to have takeover price of (39.23 M) with market capitalization of 215.91 M, debt of 4.85 M, and cash on hands of 267.13 M. The negative valuation of Molecular Partners may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should thoroughly investigate all of the Molecular Partners fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(39.23 M) | 215.91 M | 4.85 M | 267.13 M |
Molecular Partners Investor Information
About 14.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.89. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Molecular Partners had not issued any dividends in recent years. Based on the key indicators related to Molecular Partners' liquidity, profitability, solvency, and operating efficiencyBased on the analysis of, Molecular Partners AG is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Molecular Partners Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Molecular Partners has an asset utilization ratio of 5.4 percent. This indicates that the Company is making ₣0.054 for each dollar of assets. An increasing asset utilization means that Molecular Partners AG is more efficient with each dollar of assets it utilizes for everyday operations.Molecular Partners Ownership Allocation
Molecular Partners maintains a total of 36.04 Million outstanding shares. 30% of Molecular Partners outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Molecular Partners Profitability Analysis
The company reported the revenue of 9.33 M. Net Loss for the year was (63.78 M) with loss before overhead, payroll, taxes, and interest of (45.96 M).About Molecular Partners Valuation
Our relative valuation model uses a comparative analysis of Molecular Partners. We calculate exposure to Molecular Partners's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Molecular Partners's related companies.Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland. MOLECULAR PARTNERS operates under Biotechnology classification in Switzerland and is traded on Switzerland Exchange. It employs 163 people.
8 Steps to conduct Molecular Partners' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Molecular Partners' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Molecular Partners' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Molecular Partners' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Molecular Partners' revenue streams: Identify Molecular Partners' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Molecular Partners' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Molecular Partners' growth potential: Evaluate Molecular Partners' management, business model, and growth potential.
- Determine Molecular Partners' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Molecular Partners' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Molecular Stock Analysis
When running Molecular Partners' price analysis, check to measure Molecular Partners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Molecular Partners is operating at the current time. Most of Molecular Partners' value examination focuses on studying past and present price action to predict the probability of Molecular Partners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Molecular Partners' price. Additionally, you may evaluate how the addition of Molecular Partners to your portfolios can decrease your overall portfolio volatility.